Vanguard Group Inc Crispr Therapeutics Ag Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Vanguard Group Inc holds 2,298,089 shares of CRSP stock, worth $130 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,298,089
Previous 1,769,709
29.86%
Holding current value
$130 Million
Previous $60.2 Million
85.61%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CRSP
# of Institutions
529Shares Held
68.7MCall Options Held
3.79MPut Options Held
2.29M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$576 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$317 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$208 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$185 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$161 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.42B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....